facebook
twitter
rss
account
search
search
 

FDA approves new fibrillation drug

July 2, 2009 at 11:10 AM   |   Comments

WASHINGTON, July 2 (UPI) -- The U.S. Food and Drug Administration announced approval Thursday of Multaq tablets to help maintain normal heart rhythms in patients with heart disorders.

The FDA said Multaq (dronedarone) is designed to treat atrial fibrillation or atrial flutter in patients whose hearts have returned to normal rhythm or who will undergo drug or electric-shock treatment to restore a normal heart beat.

Since Multaq might cause critical adverse reactions, including death, in patients with recent severe heart failure, officials said Multag's drug's label will contain a boxed warning, the FDA's strongest warning, cautioning the drug should not be used by such people.

Multaq is manufactured by the French pharmaceutical company Sanofi-Aventis.

© 2009 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent.
Recommended UPI Stories
Featured UPI Collection
trending
2014: The Year in Music [PHOTOS]

2014: The Year in Music [PHOTOS]

Most Popular
1
Researchers dig up earliest evidence of snail-eating
2
Tropical storm Karina looks like the number 9 from space
3
Spiders prefer the city life
4
Rock-eating bacteria discovered in buried Antarctic lake
5
Study explains why ER nurses do what they do
Trending News
Video
x
Feedback